Annals of Indian Academy of Neurology
: 2014  |  Volume : 17  |  Issue : 3  |  Page : 281--286

Major outcomes of patients with tuberculous meningitis on directly observed thrice a week regime

Thomas Iype1, Ayyappan Kunjukrishna Pillai1, Ajith Cherian1, Zinia T Nujum2, Chithra Pushpa1, Dalus Dae3, Vijayakumar Krishnapillai2,  
1 Department of Neurology, Government Medical College, Thiruvananthapuram, Kerala, India
2 Department of Community Medicine, Government Medical College, Thiruvananthapuram, Kerala, India
3 Department of Medicine, Government Medical College, Thiruvananthapuram, Kerala, India

Correspondence Address:
Thomas Iype
Department of Neurology, Government Medical College, Thiruvananthapuram - 695 011, Kerala


Background: Revised National Tuberculosis Control Programme (RNTCP) of Government of India provides intermittent thrice-a-week directly observed treatment short course (RNTCP regimen). Objective: Assessments of all-cause mortality and nine-month morbidity outcomes of patients with tuberculous meningitis (TBM) on RNTCP regimen. Materials and Methods: We prospectively followed up patients registered with RNTCP center, with a diagnosis of TBM from January 1 st , 2010 to December 31 st , 2011. Morbidity was assessed using modified Rankin Scale (mRS). Results: We had 43 patients with median duration for follow-up of 396 days and that of survivors of 425 days. Two patients defaulted. Fourteen patients (32.5%) had mRS score of 4 to 6 and 29 had mRS of 0 to 3 after 9-month treatment. Severe disability was not related to any factor on logistic regression. Severe disability was seen in one patient (6.66%) among the 15 patients with stage 1, nine (37.5%) out of 24 patients with stage 2 and three (75%) out of 4 patients with stage 3 disease. Eight patients died (18.6%) of whom 4 died during the intensive phase and 4 during the continuation phase of RNTCP regimen. Mortality was independently related to treatment failure with adjusted Hazard ratio of 8.29 (CI: 1.38-49.78) (P = 0.02). One patient (6.66%) died out of the 15 patients with stage 1 disease, 5 (20.8%) out of 24 patients with stage 2 disease and 2 (50%) out of the 4 with stage 3 disease. Discussion and Conclusion: RNTCP regimen was associated with good compliance, comparable mortality and morbidity.

How to cite this article:
Iype T, Pillai AK, Cherian A, Nujum ZT, Pushpa C, Dae D, Krishnapillai V. Major outcomes of patients with tuberculous meningitis on directly observed thrice a week regime.Ann Indian Acad Neurol 2014;17:281-286

How to cite this URL:
Iype T, Pillai AK, Cherian A, Nujum ZT, Pushpa C, Dae D, Krishnapillai V. Major outcomes of patients with tuberculous meningitis on directly observed thrice a week regime. Ann Indian Acad Neurol [serial online] 2014 [cited 2022 Nov 29 ];17:281-286
Available from:

Full Text


Tuberculous meningitis (TBM) is associated with significant neurological sequelae, high morbidity [1],[2],[3] and a high mortality rate ratio of 1.79. [4] Most treatment guidelines of TBM even though not based on randomized controlled studies, recommend daily antituberculous agents (ATT) for 12 months. [5],[6] Hence, most neurologists in India continue to give daily self-administered therapy for a variable period of 12 to 18 months, which incurs high out of pocket spending. The World Health Organization (WHO) also recommends daily regimen for 9 to 12 months and as an alternative have suggested directly observed intermittent ATT thrice a week for immune-competent patients during both intensive and continuation phases.

The Revised National Tuberculosis Control Programme (RNTCP) funded by Government of India gives intermittent thrice-a-week directly observed treatment short course (DOTS), both during intensive and continuation phases, for a total of 9 months for patients with TBM. We have been following this regimen for TBM in our institution from its inception.

There are very few reports on intermittent regimen in meningeal tuberculosis in adults. [7],[8],[9] Hence, we do not have evidence that the intermittent regimen is as good/superior/inferior to the daily regimen. We need follow-up studies in patients on intermittent regimen to guide national policies. Hence, we conducted a prospective study on patients with TBM on Government sponsored RNTCP regimen to look at the all-cause mortality, nine-month morbidity and the predictors for the same.

 Materials and Methods


This study was undertaken by the Departments of Community Medicine and Neurology, Government Medical College Hospital, Thiruvananthapuram, Kerala, a tertiary care referral center in south India, after obtaining approval from the Institutional Human Ethics Committee. Written informed consent was obtained from all the patients.


We recruited consecutive patients registered to the RNTCP clinic at our center with a diagnosis of TBM from January 1 st , 2010 to December 31 st , 2011. We diagnosed TBM based on consensus tuberculous meningitis criteria and categorized them into definite, probable and possible TBM. [10] We excluded patients below the age of 13 years and patients with Thwaites index of above four. [11] Patients with a setting for bacterial meningitis like bacterial sinusitis, otitis media, cerebrospinal fluid (CSF) rhinorrhea and patients with history of head injury and nasal or aural bleeding were excluded. We excluded patients with pre-existing renal or liver disease, and immune-compromised patients including those with retroviral positive status. We also excluded patients with premorbid visual impairment, deafness and mental retardation since it would affect the morbidity assessment. We excluded patients who died within 5 days of initiation of RNTCP regimen since their early mortality is unlikely to have been influenced by the two doses of the RNTCP regime. All patients had chest radiographs, abdominal ultrasound examination, sputum acid-fast stain (AFB) stain, human immunodeficiency virus (HIV) serology, CSF analysis including AFB smear, mycobacterial cultures and neuroimaging of brain with contrast study.

Category 1 was initiated in previously unexposed patients and category 2 for patients exposed to antituberculous agents (ATT). In the RNTCP regimen, category 1 consists of isoniazid(H) 10 mg per kg, rifampicin(R) 10 mg per kg, streptomycin(S) 750 mg (or ethambutol 30 mg per kg for those with contraindications or cannot tolerate streptomycin) and pyrazinamide(Z) 35 mg per kg given thrice a week during the intensive phase for two months followed by isoniazid and rifampicin alone thrice a week for the next seven months in the continuation phase {2(HRZS) 3/7(HR) 3}. Category 2 consists of isoniazid, rifampicin, streptomycin, pyrazinamide as in category 1, along with ethambutol (E) given thrice a week for two months followed by isoniazid, rifampicin, ethambutol, and pyrazinamide given thrice a week for the next one month during the intensive phase followed by isoniazid and rifampicin alone thrice a week for the next seven months in the continuation phase {2(HREZS) 3/1(HREZ) 3 /7(HR)3}. All patients received steroids in the initial four weeks of treatment.

Subjects came once a month during the duration of treatment and there after once every three months till December 31 st 2012. RNTCP clinic functions six days a week. In addition to this care givers were encouraged to contact the principal investigator (TI) by cellphone in case of any medical illness or life events. Discontinuation one month after initiation of ATT for more than 1 month is considered as default as per RNTCP. Patients were asked to report if there is anorexia, vomiting or high colored urine on days in which they were not taking rifampicin. Patients with such symptoms should have their liver enzymes tested and ATT stopped, if it is elevated more than 5 times the upper limit of normal. [12]


Information regarding mortality was obtained either from the family informing us on their own or from them when we enquire regarding their absence for a scheduled visit. Morbidity was assessed using modified Rankin Scale (mRS). [13] Strokes due to TBM were diagnosed from history, clinical examination findings and neuroimaging.

Age at the onset of illness, gender, stage of disease, time (in days) to presentation to the hospital from symptom onset, time (in days) to treatment initiation from symptom onset, Thwaites index, treatment category, presence of associated tuberculoma, cerebral infarcts, cerebrospinal fluid (CSF) pleocytosis >200 cells/ml, elevated CSF protein >200 mg/dl, tuberculous radiculomyelitis (spinal arachnoiditis), concomitant alcohol use of >14 drink per week in male and >11 drink per week in women, diabetes, steroid use prior to treatment were assessed as variables, which could determine the outcomes (mortality and morbidity).

Statistical Analysis: Mortality rates were expressed in percentage. We used GraphPad Prism 5 and Statistical Package for the Social Sciences software (SPSS, version 11.0) for statistical analysis. We used Kaplan Meier curves for survival analysis and Cox regression for unadjusted and adjusted hazard ratios on predictors of mortality. Risk factor for morbidity was done using Chi square test for bivariable analysis and logistic regression for multivariable analysis.


Forty-seven patients with a diagnosis of TBM were registered between January 1 st , 2010 and December 31 st , 2011. Two patients died within 5 days of starting RNTCP regimen and 2 were lost for follow-up [Figure 1]. The last (43 rd patient) was recruited on 7/12/2011 and his treatment was completed on 10/9/2012. We had two patients with definite, 23 patients with probable and 18 patients with possible TBM as per the consensus criteria. The baseline characteristics are given in [Table 1]. Age at presentation ranged from 14 to 61 years. Majority had stage 2 disease [Table 1] Excess alcohol use was seen in 13 out of 22 male patients and none among the 21 females. Sixteen patients (37.2%) had cranial nerve deficits, 14 (32.6%) had arteritis, 9 (20.9%) had hydrocephalus, 7 (16.3%) had seizures, 5(11.6%) had tuberculoma, 3 (7%) had spinal arachnoiditis, and 1 (2.3%) had caries spine during the hospital stay.{Figure 1}{Table 1}

Thirteen patients (30.2%) had indirect evidence of tuberculosis elsewhere in the body. Chest radiograph was abnormal in 11 patients (25.6%). Milliary mottling was seen in 2 patients, upper zone lesions in 5 patients, hilar adenopathy in 2 patients and lower zone lesions in 2 patients. One patient with lower zone lesion and another patient with milliary lesions on chest radiograph had documented splenomegaly. One patient had hydronephrosis due to tuberculous pyelonephritis. Another patient had supraclavicular lymphadenopathy, and ultrasound showed multiple conglomerate lymph nodes in celiac region with multiple large nodes in aorto caval, retrocaval and para-aortic region. We did CSF polymerase chain reaction (PCR) in 4 patients, out of which 2 were positive. We did CSF AFB smear and culture in all our patients but all turned out to be negative.

Two patients (40%) had seizures out of the 5 TBM patients with associated tuberculoma. In contrast, only five patients (13.1%) had seizures out of 38 TBM patients without tuberculoma. None of the TBM patients with tuberculoma died. The tuberculoma disappeared in all within 9 months of treatment except for one patient, who had to be given ATT for 12 months for the complete disappearance of tuberculoma.

All were on category 1 RNTCP regimen except two patients who were on category 2. All patients in category 1 took injection streptomycin. Thirty-five patients (81.4%) completed full 9 month treatment. ATT was inadvertently stopped after 6 months in 3 and after 7 months in 2 patients by the RNTCP DOTS providers. One patient who was given ATT for only 7 months and did not take medication for a period of 38 days, comes under the definition of default. We had another patient who defaulted (after 4 month ATT) following development of hepatitis. ATT was given for 12 months for a patient with associated tuberculoma and for 15 months for a patient with spinal arachnoiditis. The median duration of follow-up of the entire cohort (both dead and surviving) was 396 days and that of survivors alone was 425 days.

Eight patients (18.6%) had paradoxical reaction in the form of increase in size of existing tuberculoma or development of new tuberculoma, out of whom 2 died and 5 had severe morbidity (mRS 4 to 6). Four patients (9.3%) developed treatment failure, three during the fourth month and one patient (INH resistant open case of pulmonary tuberculosis) during the ninth month of ATT. One patient who completed 9 month RNTCP regimen had relapse of meningitis 3 months after stopping medication and he responded to standard daily regimen of ATT.

Four patients (9.3%) developed hepatitis, one patient at the end of a month, two patients at 4 months and one patient at 7 months. All 4 of them had anorexia and one patient had vomiting too.

Eight patients (18.6%) died during the follow-up and had a median duration of follow-up of 74 days [Figure 2]. Majority (7/ 8) died within 5 months of initiation of treatment. Four died during the intensive phase and the rest four died during the continuation phase. There were no deaths during the post treatment follow-up period. The cause of death was not verified by autopsy. Interview by the principal investigator (TI) of the care givers of patients, who died, suggested TBM or its complications as the most likely cause. All 4 patients who died within 3 months of starting treatment had arteritis, but only 1 out of the 4 patients who died after 3 months treatment had arteritis (P = 0.1429). Three out of the 4 patients who died after 3 months of RNTCP regimen had relapse of meningitis. These 3 who died after 3 months of RNTCP regimen and one of the 4 patients who died within 3 months of RNTCP regimen had hydrocephalus (P = 0.4857). One person who died 3 months after starting RNTCP regimen had pre-existing psychosis and died of seizure and aspiration pneumonia. Two out of the 4 patients who died 3 months after starting RNTCP regimen were on category 2. One patient (6.66%) out of the 15 patients with stage 1 disease, 5 (20.8%) out of 24 patients with stage 2 disease and 2 (50%) out of the 4 with stage 3 disease died. {Figure 2}

Kaplan Meier survival analysis showed that the mortality was related to hydrocephalus, drug resistance, treatment failure, category 2 treatment and arteritis [Table 2]. Treatment failure was the only significant variable with adjusted Hazard ratio of 8.29 (CI: 1.38-49.78) (P = 0.02) on Cox regression.

Fourteen patients (32.5%) died or had severe disability (mRS 4 to 6) and 29 had mild to moderate disability (mRS 0 to 3) at 9 month treatment. Severe disability was seen in one patient (6.66%) among 15 patients with stage 1, nine (37.5%) out of 24 patients with stage 2 and three (75%) out of 4 patients with stage 3 disease. Spinal arachnoiditis was seen in 2 of our patients with mRS 4 to 6 and in one among those patients with mRS of 0 to 3.{Table 2}

Severe disability was related to stage 2 and 3 disease, Thwaites index of ≥−2, paradoxical reaction, and history of contact with pulmonary tuberculosis [Table 3]. But none of the above factors were significant on logistic regression.{Table 3}

We found that through the RNTCP programme patients were getting the directly observed medication except in two patients. Medication was directly observed only once a week in one case during the intensive phase, which was immediately rectified with the intervention of the RNTCP officer. The other case case was also not directly observed and she was readmitted with meningitis and hydrocephalus 3 months after the initiation of ATT and she died on the 16 th day of hospitalization. Out of the six patients where ATT was inadvertently stopped prior to completion of 9 month therapy, 5 were due to lack of awareness of RNTCP field staff regarding the duration of treatment for TBM. The sixth patient stopped ATT after 124 days due to drug induced hepatitis. None of these 6 patients had treatment failure, relapse or mortality during the study period.


Current work is unique from other studies of TBM [14],[15] , in that it was prospective, had only adult patients and all were on intermittent thrice a week DOTS.

The mortality rate in our study (18.6%) was similar to the studies with daily regimen (17 to 43%). [3],[16],[17],[18],[19] Our observation of mortality during the continuation phase is consistent with the study from Texas. [15] They observed mortality after completion of treatment, unlike in our case, probably due to their longer mean follow-up of 3.76 ± 2.63 years in patients with proven TBM and 4.51 ± 2.09 years in patients with non-proven TBM.

There are many causes for deterioration during the initial 6 weeks of daily ATT, which include development of hydrocephalus, infarcts, exudates and granulomas. [20] We found mortality to be associated with hydrocephalus, drug resistance, treatment failure, arteritis and category 2 treatment on bivariate analysis. Hydrocephalus [21],[22] , isoniazid resistance [23] , increasing age [21],[24],[25],[26] , duration of illness at the time of admission [27] , delayed treatment [28] , altered consciousness [25],[28],[29] , stage III at presentation [27],[30] , convulsions [28] , lower CSF lymphocytes [29] , low CSF glucose [30] low CSF/blood glucose ratio [30] , high protein levels [30] , computerized tomography (CT) scan abnormality [30] , HIV positivity [2],[24] , disseminated tuberculosis [2] , excess alcohol use [24] , black race [17] , absence of corticosteroid use [17] , no treatment supporters [2] and residence in a nursing home [24] , are known to be associated with higher mortality.

One-third (32.5%) of our patients either died or had severe morbidity, which is similar to the prevalence in patients on daily regimen (29 to 60%). [3],[16],[17],[18],[19] In a retrospective study, the mortality was 17% and morbidity 13% at the end of 6 months with daily treatment. [19] In another study, at nine-month follow-up, 29% patients with TBM had either died or had severe disability. [18] Yet another study showed 22% mortality, 13% severe and 12% moderate disabilities. [3]

Even though the association with stage of disease and morbidity is well known [27],[31] , the association of severe disability with paradoxical reaction, Thwaites index and history of contact with pulmonary tuberculosis patient as shown by our study is novel. Duration of illness prior to admission [27] , extra-meningeal tuberculosis [28] , cranial nerve palsy [28],[32] , focal neurological deficits [28] , drowsiness [28] and hydrocephalus [22] are also documented to be associated with poor outcome. Kalita et al. has shown that infarct, Glasgow coma scale, and stage of meningeal tuberculosis predict the outcomes at 6 and 12 months of follow-up. [14]

Patients with TBM can have neurological sequel. [27],[30] Neurological deficits at 1 year of follow-up are known to correlate with the deficit at admission. [33] Stroke occurred in 30-45% of patients with TBM and it was an independent factor for poor outcome. [34],[35] However, stroke was not a factor in our patients with mRS 4 to 6. Spinal arachnoiditis presents with paraparesis and sphincter incontinence. [36] Hence, early detection and treatment of TBM with and without spinal arachnoiditis with combination of ATT and steroids may be useful to prevent residual deficits and disability.

We did not find any relation between outcome and tuberculoma. There are conflicting reports in literature with some suggesting prognosis to be similar in TBM with and without tuberculoma, [18] while others showed poorer outcome in patients with tuberculoma. [37] We found that in some patients the presence of tuberculoma necessitated duration of treatment >9 months till the tuberculoma disappeared.

The main advantage of the RNTCP regimen is the associated good compliance, which has an important influence on the mortality and morbidity. We found that there is a need to increase the awareness of duration of treatment for TBM among the RNTCP DOTS providers. A good liaison between the treating Neurologist or the Physician with the DOTS provider is essential in the treatment of TBM because of the special issues of paradoxical reactions, recurrence of meningitis and decision on duration of treatment in case of patients with associated tuberculomas. We found that there was flexibility within the RNTCP programme in which we could ask for extension of intensive phase in genuine cases for a month. This was also true for extension of continuation phase if the associated granuloma has not completely subsided.

The strength of the study is that it was a prospective study of patients with TBM on intermittent regime with a reasonable follow-up documenting the mortality and morbidity. Our study has shown that some patients die following treatment failure both during the intensive as well as continuation phase after an initial response as with any regimen for TBM. The limitation of the current study is that very few were definite cases of TBM. Both patients on category 2 with history of exposure to ATT initially responded but had relapse of meningitis and died probably due to drug resistance. We have not systematically looked at drug resistance in our patients even though we presume that multi-drug resistant tuberculosis might be contributing to the mortality at least in some cases. Even though drug resistance is a risk factor for increased mortality, [23] there are contrary reports that isoniazid and streptomycin resistance do not increase the risk of death. [38] The fact that one patient who had relapse of meningitis after completion of 9 months of RNTCP regimen and responded to restart of intensive phase of daily regimen points to the fact that daily regimen still worked when there was relapse after completion of intermittent regimen.

Overall, RNTCP regimen was associated with good compliance, comparable mortality and morbidity. Only randomized controlled studies will tell us, if there is a difference between daily regimen and of intermittent thrice a week regimen on the mortality and morbidity of patients with TBM. However, as with other regimen, there was treatment failure and case fatality, which points to the search for better regimen and to designing newer drugs. This is especially true in the context of suspected emerging drug resistance.


We thank Professor Rajmohan K for his critical review of the article. We acknowledge the receipt of grant from the State Board of Medical Research, Government of Kerala.


1Christensen AS, Andersen AB, Thomsen VO, Andersen PH, Johansen IS. Tuberculous meningitis in Denmark: A review of 50 cases. BMC Infect Dis 2011;11:47.
2Burton NT, Forson A, Lurie MN, Kudzawu S, Kwarteng E, Kwara A. Factors associated with mortality and default among patients with tuberculosis attending a teaching hospital clinic in Accra, Ghana. Trans R Soc Trop Med Hyg 2011;105:675-82.
3Anderson NE, Somaratne J, Mason DF, Holland D, Thomas MG. Neurological and systemic complications of tuberculous meningitis and its treatment at Auckland City Hospital, New Zealand. J Clin Neurosci 2010;17:1114-8.
4Christensen AS, Roed C, Omland LH, Andersen PH, Obel N, Andersen ÅB. Long-term mortality in patients with tuberculous meningitis: A Danish nationwide cohort study. PLoS One 2011;6:e27900.
5Thwaites G, Fisher M, Hemingway C, Scott G, Solomon T, Innes J, British Infection Society. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect 2009;59:167-87.
6Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al., American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-62.
7Iype T, Chacko S, Raghavan S, Mathew R, Mohan M. Preliminary report of directly observed treatment, short course in tuberculous meningitis. Ann Indian Acad Neurol 2010;13:57-60.
8Iype T, George LE, Cherian A, Kumar A, Ajitha BK, Chandy S, et al. In-hospital mortality of intermittent vs daily antitubercular regimen in patients with meningeal tuberculosis--a retrospective study. Indian J Tuberc 2012;59:6-11.
9Sharma SR, Lynrah KG, Sharma N, Lyngdoh M. Directly observed treatment, short course in tuberculous meningitis: Indian perspective. Ann Indian Acad Neurol 2013;16:82-4.
10Marais S, Thwaites G, Schoeman JF, Török ME, Misra UK, Prasad K, et al. Tuberculous meningitis: A uniform case definition for use in clinical research. Lancet Infect Dis 2010;10:803-12.
11Thwaites GE, Chau TT, Stepniewska K, Phu NH, Chuong LV, Sinh DX, et al. Diagnosis of adult tuberculous meningitis by use of clinical and laboratory features. Lancet 2002;360:1287-92.
12Byrd RB, Horn BR, Solomon DA, Griggs GA. Toxic effects of isoniazid in tuberculosis chemoprophylaxis. Role of biochemical monitoring in 1,000 patients. JAMA 1979;241:1239-41.
13Wolfe CD, Taub NA, Woodrow EJ, Burney PG. Assessment of scales of disability and handicap for stroke patients. Stroke 1991;22:1242-4.
14Kalita J, Misra UK. Outcome of tuberculous meningitis at 6 and 12 months: A multiple regression analysis. Int J Tuberc Lung Dis 1999;3:261-5.
15Shaw JE, Pasipanodya JG, Gumbo T. Meningeal tuberculosis: High long-term mortality despite standard therapy. Medicine (Baltimore) 2010;89:189-95.
16Porkert MT, Sotir M, Parrott-Moore P, Blumberg HM. Tuberculous meningitis at a large inner-city medical center. Am J Med Sci 1997;313:325-31.
17Yechoor VK, Shandera WX, Rodriguez P, Cate TR. Tuberculous meningitis among adults with and without HIV infection. Experience in an urban public hospital. Arch Intern Med 1996;156:1710-6.
18Anuradha HK, Garg RK, Sinha MK, Agarwal A, Verma R, Singh MK, et al. Intracranial tuberculomas in patients with tuberculous meningitis: Predictors and prognostic significance. Int J Tuberc Lung Dis 2011;15:234-9.
19Pehlivanoglu F, Yasar KK, Sengoz G. Tuberculous meningitis in adults: A review of 160 cases. ScientificWorldJournal 2012;2012:169028.
20Ranjan P, Kalita J, Misra UK. Serial study of clinical and CT changes in tuberculous meningitis. Neuroradiology 2003;45:277-82.
21Hsu PC, Yang CC, Ye JJ, Huang PY, Chiang PC, Lee MH. Prognostic factors of tuberculous meningitis in adults: A 6-year retrospective study at a tertiary hospital in northern Taiwan. J Microbiol Immunol Infect 2010;43:111-8.
22Tan EK, Chee MW, Chan LL, Lee YL. Culture positive tuberculous meningitis: Clinical indicators of poor prognosis. Clin Neurol Neurosurg 1999;101:157-60.
23Vinnard C, Winston CA, Wileyto EP, Macgregor RR, Bisson GP. Isoniazid resistance and death in patients with tuberculous meningitis: Retrospective cohort study. BMJ 2010;341:c4451.
24Nguyen LT, Hamilton CD, Xia Q, Stout JE. Mortality before or during treatment among tuberculosis patients in North Carolina, 1993-2003. Int J Tuberc Lung Dis 2011;15:257-62.
25Yasar KK, Pehlivanoglu F, Sengoz G. Predictors of mortality in tuberculous meningitis: A multivariate analysis of 160 cases. Int J Tuberc Lung Dis 2010;14:1330-5.
26George EL, Iype T, Cherian A, Chandy S, Kumar A, Balakrishnan A, et al. Predictors of mortality in patients with meningeal tuberculosis. Neurol India 2012;60:18-22.
27Girgis NI, Sultan Y, Farid Z, Mansour MM, Erian MW, Hanna LS, et al. Tuberculosis meningitis, Abbassia Fever Hospital-Naval Medical Research Unit No. 3-Cairo, Egypt, from 1976 to 1996. Am J Trop Med Hyg 1998;58:28-34.
28Hosoglu S, Geyik MF, Balik I, Aygen B, Erol S, Aygencel TG, et al. Predictors of outcome in patients with tuberculous meningitis. Int J Tuberc Lung Dis 2002;6:64-70.
29Lau KK, Yu IT, Chan AC, Wong LK, Tam CM, Sheng B, et al., Hong Kong Tuberculous Meningitis Study Group. A registry of tuberculous meningitis in Hong Kong. Int J Tuberc Lung Dis 2005;9:1391-7.
30Hosoðlu S, Ayaz C, Geyik MF, Kökoðlu OF, Ceviz A. Tuberculous meningitis in adults: An eleven-year review. Int J Tuberc Lung Dis 1998;2:553-7.
31Wang JT, Hung CC, Sheng WH, Wang JY, Chang SC, Luh KT. Prognosis of tuberculous meningitis in adults in the era of modern antituberculous chemotherapy. J Microbiol Immunol Infect 2002;35:215-22.
32Sharma P, Garg RK, Verma R, Singh MK, Shukla R. Incidence, predictors and prognostic value of cranial nerve involvement in patients with tuberculous meningitis: A retrospective evaluation. Eur J Intern Med 2011;22:289-95.
33Kalita J, Misra UK, Ranjan P. Predictors of long-term neurological sequelae of tuberculous meningitis: A multivariate analysis. Eur J Neurol 2007;14:33-7.
34Anuradha HK, Garg RK, Agarwal A, Sinha MK, Verma R, Singh MK, et al. Predictors of stroke in patients of tuberculous meningitis and its effect on the outcome. QJM 2010;103:671-8.
35Kalita J, Misra UK, Nair PP. Predictors of stroke and its significance in the outcome of tuberculous meningitis. J Stroke Cerebrovasc Dis 2009;18:251-8.
36Moghtaderi A, Alavi Naini R. Tuberculous radiculomyelitis: Review and presentation of five patients. Int J Tuberc Lung Dis 2003;7:1186-90.
37Pehlivanoglu F1, Yasar KK, Sengoz G. Prognostic factors of neurological sequel in adult patients with tuberculous meningitis. Neurosciences (Riyadh) 2010;15:262-7.
38Thwaites GE, Lan NT, Dung NH, Quy HT, Oanh DT, Thoa NT, et al. Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis. J Infect Dis 2005;192:79-88.